Hi, what are you looking for?
By Chris Wack
Minerva Neurosciences, Inc. shares were up 25%, to $3.50, after the company said that the U.S. Food and Drug Administration filed its New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
The company said the decision to file the NDA follows its request for formal dispute…
Read the full article here
This article was written by Follow Harrison is a financial analyst who has been writing on Seeking Alpha since 2018 and has closely followed...
Illumina, Inc. (NASDAQ:ILMN) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra – CFOSallilyn Schwartz – VP...
This article was written by Follow Long-only investment, evaluating companies from an operational, buy-and-hold perspective.Quipus Capital does not focus on market-driven dynamics and future...
America’s Car-Mart, Inc. (NASDAQ:CRMT) Q2 2025 Earnings Conference Call December 5, 2024 9:00 AM ET Company Participants Vickie Judy – CFODoug Campbell – President...
